Attenuated GABAergic Signaling in Intestinal Epithelium Contributes to Pathogenesis of Ulcerative Colitis

Digestive Diseases and Sciences

Volumn 62, Issue 10, 2017, Pages 2768-2779

  Aggarwal, Surbhi ^a   Ahuja, Vineet ^b   Paul, Jaishree ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cytokines; Enteric nervous system; GABA; GABA receptor; Inflammation; Neurotransmitter; p38 MAPK; Ulcerative colitis

Indexed keywords

4 AMINOBUTYRIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR; 4 AMINOBUTYRIC ACID RECEPTOR; AUTACOID; CYTOKINE;

ADULT; ARTICLE; BACTERIAL COUNT; BACTEROIDES FRAGILIS; BACTEROIDES VULGATUS; BIFIDOBACTERIUM; BIFIDOBACTERIUM DENTIUM; COLON BIOPSY; COLON EPITHELIUM; COLON MUCOSA; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; GABAERGIC TRANSMISSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; BACTERIUM; BIOPSY; CASE CONTROL STUDY; CHEMISTRY; COLON; DOWN REGULATION; FECES; GENETICS; INTESTINE MUCOSA; METABOLISM; MICROBIOLOGY; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADULT; BACTERIA; BIOPSY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; CYTOKINES; DOWN-REGULATION; FECES; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; INFLAMMATION MEDIATORS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, GABA; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 85021694535     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-017-4662-3     Document Type: Article

References (51)

1. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflamm. 2010;7:37.
2. Chandrasekharan B, Nezami BG, Srinivasan S. Emerging neuropeptide targets in inflammation: NPY and VIP. Am J Physiol Gastrointest Liver Physiol. 2013;304:G949–G957.
3. Goyal RK, Hirano I. The enteric nervous system. N Engl J Med. 1996;334:1106–1115.
4. Jin Z, Mendu SK, Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids. 2013;45:87–94.
5. Sallam MY, El-Gowilly SM, Abdel-Galil AG, El-Mas MM. Central GABAA receptors are involved in inflammatory and cardiovascular consequences of endotoxemia in conscious rats. Naunyn Schmiedebergs Arch Pharmacol. 2016;389:279–288.
6. Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity. 2011;44:465–470.
7. Oresic M, Simell S, Sysi-Aho M, et al. Dysregulation of lipid and amino acid metabolism precedes islet autoimmunity in children who later progress to type 1 diabetes. J Exp Med. 2008;205:2975–2984.
8. Bhat R, Axtell R, Mitra A, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA. 2010;107:2580–2585.
9. Nigam R, El-Nour H, Amatya B, Nordlind K. GABA and GABA(A) receptor expression on immune cells in psoriasis: a pathophysiological role. Arch Dermatol Res. 2010;302:507–515.
10. Duthey B, Hubner A, Diehl S, Boehncke S, Pfeffer J, Boehncke WH. Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010;19:661–666.
11. Xiang YY, Wang S, Liu M, et al. A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. Nat Med. 2007;13:862–867.
12. Li Y, Xiang YY, Lu WY, Liu C, Li J. A novel role of intestine epithelial GABAergic signaling in regulating intestinal fluid secretion. Am J Physiol Gastrointest Liver Physiol. 2012;303:G453–G460.
13. Zhang X, Zhang R, Zheng Y, et al. Expression of gamma-aminobutyric acid receptors on neoplastic growth and prediction of prognosis in non-small cell lung cancer. J Transl Med. 2013;11:102.
14. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol. 2009;25:503–511.
15. Pokusaeva K, Johnson C, Luk B, et al. GABA-producing Bifidobacterium dentium modulates visceral sensitivity in the intestine. Neurogastroenterol Motil. 2017;29:e12904. doi:10.1111/nmo.12904.
16. Barrett E, Ross RP, O’Toole PW, Fitzgerald GF, Stanton C. gamma-Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol. 2012;113:411–417.
17. Rios-Covian D, Sanchez B, Salazar N, et al. Different metabolic features of Bacteroides fragilis growing in the presence of glucose and exopolysaccharides of bifidobacteria. Front Microbiol. 2015;6:825.
18. Demakova EV, Korobov VP, Lemkina LM. Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis. Klin Lab Diagn. 2003;4:15–17.
19. Johnson SK, Haun RS. The gamma-aminobutyric acid A receptor pi subunit is overexpressed in pancreatic adenocarcinomas. JOP. 2005;6:136–142.
20. Paul AM, Branton WG, Walsh JG, et al. GABA transport and neuroinflammation are coupled in multiple sclerosis: regulation of the GABA transporter-2 by ganaxolone. Neuroscience. 2014;273:24–38.
21. Taneera J, Jin Z, Jin Y, et al. γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetes. Diabetologia. 2012;55:1985–1994.
22. Kleinrok Z, Matuszek M, Jesipowicz J, Matuszek B, Opolski A, Radzikowski C. GABA content and GAD activity in colon tumors taken from patients with colon cancer or from xenografted human colon cancer cells growing as s.c. tumors in athymic nu/nu mice. J Physiol Pharmacol. 1998;49:303–310.
23. Matuszek M, Jesipowicz M, Kleinrok Z. GABA content and GAD activity in gastric cancer. Med Sci Monit. 2001;7:377–381.
24. Kelley JM, Hughes LB, Bridges SL Jr. Does gamma-aminobutyric acid (GABA) influence the development of chronic inflammation in rheumatoid arthritis? J Neuroinflamm. 2008;5:1.
25. Hollenbach E, Neumann M, Vieth M, Roessner A, Malfertheiner P, Naumann M. Inhibition of p38 MAP kinase- and RICK/NF-kappaB-signaling suppresses inflammatory bowel disease. FASEB J. 2004;18:1550–1552.
26. Sun A, Liu M, Nguyen XV, Bing G. P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol. 2003;183:394–405.
27. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer’s disease. Neurobiol Aging. 2000;21:383–421.
28. Winzen R, Kracht M, Ritter B, et al. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J. 1999;18:4969–4980.
29. Zhao X, Kang B, Lu C, et al. Evaluation of p38 MAPK pathway as a molecular signature in ulcerative colitis. J Proteome Res. 2011;10:2216–2225.
30. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991–1030.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 2001;25:402–408.
32. Dionisio L, Jose De Rosa M, Bouzat C, Esandi Mdel C. An intrinsic GABAergic system in human lymphocytes. Neuropharmacology. 2011;60:513–519.
33. Lehre AC, Rowley NM, Zhou Y, et al. Deletion of the betaine-GABA transporter (BGT1; slc6a12) gene does not affect seizure thresholds of adult mice. Epilepsy Res. 2011;95:70–81.
34. Docena G, Rovedatti L, Kruidenier L, et al. Down-regulation of p38 mitogen-activated protein kinase activation and proinflammatory cytokine production by mitogen-activated protein kinase inhibitors in inflammatory bowel disease. Clin Exp Immunol. 2010;162:108–115.
35. Hyland NP, Cryan JF. A Gut Feeling about GABA: focus on GABA(B) receptors. Front Pharmacol. 2010;1:124.
36. Jembrek MJ, Auteri M, Serio R, Vlainic J. GABAergic system in action: connection to gastrointestinal stress-related disorders. Curr Pharm Des. 2017. doi:10.2174/1381612823666170209155753.
37. Hosinian M, Qujeq D, Ahmadi Ahangar A. The relation between GABA and l-arginine levels with some stroke risk factors in acute ischemic stroke patients. Int J Mol Cell Med. 2016;5:100–105.
38. Jun HS, Khil LY, Yoon JW. Role of glutamic acid decarboxylase in the pathogenesis of type 1 diabetes. Cell Mol Life Sci. 2002;59:1892–1901.
39. Sherif FM, Ahmed SS. Basic aspects of GABA-transaminase in neuropsychiatric disorders. Clin Biochem. 1995;28:145–154.
40. Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213:1–47.
41. Tiurenkov IN, Perfilova VN. Perfilova VN [GABA receptors: structure and functions]. Eksp Klin Farmakol. 2010;73:43–48.
42. Condic ML, Letourneau PC. Ligand-induced changes in integrin expression regulate neuronal adhesion and neurite outgrowth. Nature. 1997;389:852–856.
43. Jiang X, Su L, Zhang Q, et al. GABAB receptor complex as a potential target for tumor therapy. J Histochem Cytochem. 2012;60:269–279.
44. Rane MJ, Gozal D, Butt W, et al. Gamma-amino butyric acid type B receptors stimulate neutrophil chemotaxis during ischemia-reperfusion. J Immunol. 2005;174:7242–7249.
45. Su J, Yin J, Qin W, Sha S, Xu J, Jiang C. Role for pro-inflammatory cytokines in regulating expression of GABA transporter type 1 and 3 in specific brain regions of kainic acid-induced status epilepticus. Neurochem Res. 2015;40:621–627.
46. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756–1767.
47. Dudley JT, Sirota M, Shenoy M, et al. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011;3:96ra76.
48. Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res. 2015;93:11–21.
49. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015;37:47–55.
50. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015;2015:505878.
51. Schultz M, Veltkamp C, Dieleman LA, et al. Lactobacillus plantarum 299 V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis. 2002;8:71–80.